Evaluation of Intravenous Pamidronate Administration in 33 Cancer‐Bearing Dogs with Primary or Secondary Bone Involvement

The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor‐bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N‐telopeptide excretion ( P = .042) and enhanced bone mineral density of the primary tumor measured with dual‐energy x‐ray absorptiometry ( P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor‐bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption.